Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients-The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy.
LC-MS/MS
TDM
kidney and liver transplantation
tacrolimus
tissue concentration
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
21
07
2021
revised:
22
09
2021
accepted:
23
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Tacrolimus (TAC) has a narrow therapeutic index and highly variable pharmacokinetic characteristics. Close monitoring of the TAC concentrations is required in order to avoid the risk of acute rejection or adverse drug reaction. The results in some studies indicate that inter-tissue TAC concentrations can be a better predictor with regards to acute rejection episode than TAC concentration in whole blood. Therefore, the aim of the study was to assess the correlation between dosage, blood, hepatic and kidney tissue concentration of TAC measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) and clinical outcomes in a larger cohort of 100 liver and renal adult transplant recipients. Dried biopsies were weighed, mechanically homogenized and then the samples were treated with a mixture of zinc sulfate-acetonitrile to perform protein precipitation. After centrifugation, the extraction with
Identifiants
pubmed: 34683869
pii: pharmaceutics13101576
doi: 10.3390/pharmaceutics13101576
pmc: PMC8538499
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Pharmacol. 2019 Mar;59(3):309-325
pubmed: 30371942
Molecules. 2020 Sep 03;25(17):
pubmed: 32899296
Ther Drug Monit. 2009 Apr;31(2):178-86
pubmed: 19057467
Biomed Chromatogr. 2019 Jan;33(1):e4416
pubmed: 30362145
J Chromatogr A. 2016 Dec 2;1475:55-63
pubmed: 27837999
Pharmacol Res. 2016 Sep;111:610-618
pubmed: 27468645
Ther Drug Monit. 2013 Oct;35(5):617-23
pubmed: 23921430
Ther Drug Monit. 2007 Jun;29(3):340-8
pubmed: 17529892
Clin Ther. 2002 Mar;24(3):330-50; discussion 329
pubmed: 11952020
Transpl Int. 2012 Jan;25(1):41-7
pubmed: 21981711
PLoS One. 2016 Apr 15;11(4):e0153491
pubmed: 27082871
J Pharm Biomed Anal. 2019 Mar 20;166:40-51
pubmed: 30609393
J Pharm Biomed Anal. 2015 Mar 25;107:512-7
pubmed: 25698619
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:220-227
pubmed: 30530114
Br J Clin Pharmacol. 2021 Oct;87(10):3901-3909
pubmed: 33646566
Bioanalysis. 2010 Jun;2(6):1141-53
pubmed: 21083213
Ther Drug Monit. 2011 Dec;33(6):688-93
pubmed: 22105584
Ther Drug Monit. 2018 Oct;40(5):558-566
pubmed: 30086087
Ther Drug Monit. 2018 Jun;40(3):292-300
pubmed: 29578937
Clin Biochem. 2011 Jan;44(1):14-20
pubmed: 20599871
Hepatology. 1995 Jan;21(1):70-6
pubmed: 7528712
Clin Biochem. 2013 Oct;46(15):1538-41
pubmed: 23454394
Pharmacol Res. 2013 Aug;74:109-12
pubmed: 23792083
Ther Drug Monit. 2019 Jun;41(3):261-307
pubmed: 31045868
Bioanalysis. 2015;7(8):1037-58
pubmed: 25966013
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 15;945-946:171-7
pubmed: 24342510